返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® EP Attends CSA 2017

[2017-07-07] 

Hangzhou, China – From June 8 to June 10, Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") attended the 2017 Annual Meeting of the Heart Rhythm Special Committee of Chinese Medical Doctor Association ("CSA 2017") held in Hangzhou, Zhejiang Province, and hosted a satellite meeting "Columbus™: Navigation for the Heart." The CSA 2017 was sponsored by the Heart Rhythm Special Committee of Chinese Medical Doctor Association and organized by Chinese Society of Pacing and Electrophysiology.
 
On June 9, MicroPort® EP hosted a satellite meeting, co-chaired by Professor Qiangsun Zheng of the Second Affiliated Hospital of Xi'an Jiaotong University, Professor Pingzhen Yang of Zhujiang Hospital of Southern Medical University, Professor Jing Zhou of Peking University First Hospital, and Professor Jihai Fan of the 445th Hospital of Chinese People's Liberation Army. In the beginning, Professor Qiangsun Zheng said: "In this satellite meeting, we will share cases with Columbus™ 3D EP Navigation System ('Columbus™') performed in several EP centers since the launch of Columbus™ in China, through which we hope to provide you with a better understanding in the excellent performance of the domestically made system."
 
During the meeting, Professor Xudong Song of Zhujiang Hospital of Southern Medical University shared a case in which Columbus™ was used to treat a complex atrial tachycardia, and explained in detail the treatment method and mapping tips in treating the septal atrial tachycardia of the 94-year-old male patient. Professor Yuchuan Wang of Peking University First Hospital shared a case of treating left posterior fascicular ventricular tachycardia with Columbus™. Professor Wang said, he was impressed by the stable performance of Columbus™, and its full curve display facilitates the physicians to observe the positioning of the catheter and treatment effect. Professor Lanyan Guo of Xijing Hospital said, according to her clinical experience, the domestically made 3D mapping system can largely reduce the X-ray exposure and improve the ablation effect. She also expressed her expectation that the domestically made system can deliver more updated function to keep up with the imported products. Professor Songhai Wen of Southeast Guizhou People's Hospital compared Columbus™ with several competitors' products in the market such as Carto 3 and Ensite Velocity and emphasized the benefits of the domestically made system and its matching catheter for patients, such as lowered treatment cost. Meanwhile, the presidium experts and speakers had hot discussions with attendees regarding the clinical experience in Columbus™.
 
In the end of the satellite meeting, Professor Pingzhen Yang addressed a speech. He said: "Based on decades of research and development, the imported 3D mapping systems no wonder have superior advantages over the domestically made ones and are worth learning from by the domestic medical device developers. Products like Columbus™ to some extent represent the quality of China's high-end medical device, and they also signify the substitution of imported products with domestic-innovated ones. We hope that Columbus™ keeps improving and upgrading to become the industry leader. "

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MPSC Signs Investment Agreement with Zenomics to Promote the Translation of "Smart" Insulin Devices
[Next]:MicroPort® OrthoRecon Hosts SuperPath™ Training Course